[The effect of therapy on the immunological indices in patients with skin lymphomas and Kaposi's sarcoma].
Manifest changes in the immunity status are detected in lymphoproliferative diseases of the skin and in Kaposi's sarcoma. Therapy results in elevation of the initially lowered levels of T mu- and T gamma-cells, this being a favorable result. Scintillation of T mu- and T gamma-cells may be used to monitor the efficacy of therapy in such patients.
Faradzhev
Z G
ZG
Mazina
N M
NM
Ivshina
A V
AV
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002908:Chronic Disease; D006801:Humans; D007213:Indomethacin / Q000008:administration & dosage; D007370:Interferon Type I / Q000008:administration & dosage; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D008206:Lymphatic Diseases / Q000188:drug therapy / Q000276:immunology; D008223:Lymphoma / Q000188:drug therapy / Q000276:immunology*; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000188:drug therapy / Q000276:immunology; D011239:Prednisolone / Q000008:administration & dosage; D011447:Prospidium / Q000008:administration & dosage; D011994:Recombinant Proteins; D012514:Sarcoma, Kaposi / Q000188:drug therapy / Q000276:immunology*; D012878:Skin Neoplasms / Q000188:drug therapy / Q000276:immunology*; D014747:Vinblastine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D014750:Vincristine; D014747:Vinblastine; D011447:Prospidium; D011239:Prednisolone; D007213:Indomethacin
Vliianie terapii na immunologicheskie pokazateli u bol'nykh limfomami kozhi i sarkomoĭ Kaposhi.